- $2.56bn
- $1.89bn
- $218.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.73 | ||
| Price to Tang. Book | 2.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.35 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19% | ||
| Return on Equity | -14.28% | ||
| Operating Margin | -81.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27.94 | 50.93 | 23.39 | 7 | 218.71 | 27.39 | 112.34 | 62.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Directors
- Timothy Shannon NEC (62)
- Yujiro Hata PRE (47)
- Paul Stone CFO (57)
- Michael Dillon SVP (54)
- Jason Throne SVP (50)
- Julie Patel VPR
- Paul Barsanti VPR
- Matthew Maurer VPR
- M. Garret Hampton IND (55)
- Susan Kelley IND (66)
- Scott Morrison IND (63)
- Terry Rosen IND (61)
- Jeffrey Stein IND (66)
- Wendy Yarno IND (66)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 11th, 2015
- Public Since
- May 23rd, 2019
- No. of Shareholders
- 8
- No. of Employees
- 145
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 87,860,920
- Address
- 7000 SHORELINE CT, SUITE 350, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.ideayabio.com/
- Phone
- +1 3026587581
- Contact
- Andres Briseno
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for IDYA
IDEAYA Biosciences Inc Annual Shareholders Meeting
Q2 2026 IDEAYA Biosciences Inc Earnings Release
Q3 2026 IDEAYA Biosciences Inc Earnings Release
Similar to IDYA
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ideaya Biosciences share price?
As of Today at 12:14 UTC, shares in Ideaya Biosciences are trading at $29.10. This share price information is delayed by 15 minutes.
How has the Ideaya Biosciences share price performed this year?
Shares in Ideaya Biosciences last closed at $29.10 and the price had moved by +55.78% over the past 365 days. In terms of relative price strength the Ideaya Biosciences share price has outperformed the S&P500 Index by +20.96% over the past year.
What are the analyst and broker recommendations for Ideaya Biosciences?
The overall consensus recommendation for Ideaya Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ideaya Biosciences dividend yield?
Ideaya Biosciences does not currently pay a dividend.
Does Ideaya Biosciences pay a dividend?
Ideaya Biosciences does not currently pay a dividend.
When does Ideaya Biosciences next pay dividends?
Ideaya Biosciences does not currently pay a dividend.
How do I buy Ideaya Biosciences shares?
To buy shares in Ideaya Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ideaya Biosciences?
As of the previous close price of $29.10, shares in Ideaya Biosciences had a market capitalisation of $2.56bn.
Where are Ideaya Biosciences shares listed?
Here are the trading details for Ideaya Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IDYA
What kind of share is Ideaya Biosciences?
Based on an overall assessment of its quality, value and momentum Ideaya Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ideaya Biosciences share price forecast for 2026?
The analyst consensus target price for shares in Ideaya Biosciences is $51.44. That is 76.77% above the last closing price of $29.10.
Analysts covering Ideaya Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$4.33 for the next financial year.
Find out moreWhat is the trend in the Ideaya Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ideaya Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -23.19%.
As of the last closing price of $29.10, shares in Ideaya Biosciences were trading -5.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ideaya Biosciences PE Ratio?
The Ideaya Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $29.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ideaya Biosciences?
Ideaya Biosciences' management team is headed by:
- Timothy Shannon - NEC
- Yujiro Hata - PRE
- Paul Stone - CFO
- Michael Dillon - SVP
- Jason Throne - SVP
- Julie Patel - VPR
- Paul Barsanti - VPR
- Matthew Maurer - VPR
- M. Garret Hampton - IND
- Susan Kelley - IND
- Scott Morrison - IND
- Terry Rosen - IND
- Jeffrey Stein - IND
- Wendy Yarno - IND